XML 43 R32.htm IDEA: XBRL DOCUMENT
v3.26.1

Collaboration Agreements (Details) | 1 Months Ended | 2 Months Ended | 3 Months Ended | 6 Months Ended | 33 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 30, 2025 USD ($) | Mar. 31, 2025 USD ($) | Jun. 30, 2024 | Mar. 31, 2024 | Sep. 30, 2023 USD ($) product performanceObligation | Apr. 30, 2023 USD ($) | Jul. 31, 2022 | Jan. 31, 2021 USD ($) target performanceObligation | Jun. 30, 2019 USD ($) candidate target | Mar. 31, 2024 | May 31, 2026 USD ($) | May 31, 2025 USD ($) | May 31, 2024 USD ($) | May 31, 2026 USD ($) | May 31, 2025 USD ($) | May 31, 2026 USD ($) | Nov. 30, 2025 USD ($) | Mar. 31, 2023 target | Dec. 31, 2019 target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  |  | $ 9,043,000 | $ 44,056,000 |  | $ 15,295,000 | $ 62,509,000 |  |  |  |
Deferred revenue, current |  |  |  |  |  |  |  |  |  |  | 13,324,000 |  |  | 13,324,000 |  | $ 13,324,000 | $ 17,580,000 |  |
License revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  |  | 0 | 30,000,000 |  | $ 0 | 30,000,000 |  |  |  |
Gilead Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Drug targets | target |  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  | 1 |
Collaboration agreement contract term |  |  |  |  |  |  |  |  | 5 years |  |  |  |  | 5 years |  |  |  |  |
Term extension |  |  | 2 years |  |  |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |
Extension payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000.0 |  |  |  |  |  |
Number of drug candidates | candidate |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  | $ 45,000,000.0 |  |  |  |  |  |  |  |  |  |
Upfront payment of additional fees |  |  |  |  |  |  |  |  | $ 3,000,000.0 |  |  |  |  |  |  |  |  |  |
Research milestones payments received |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 47,000,000.0 |  |  |  |  |
Clinical milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000.0 |  |  |  |  |
Research and development milestone payments |  |  |  |  |  |  |  |  |  |  | 508,500,000 |  |  | 508,500,000 |  | 508,500,000 |  |  |
Target licensing and reservation payments |  |  |  |  |  |  |  |  |  |  | 60,000,000.0 |  |  | 60,000,000.0 |  | 60,000,000.0 |  |  |
Certain sales milestones payments |  |  |  |  |  |  |  |  |  |  | 1,200,000,000 |  |  | 1,200,000,000 |  | 1,200,000,000 |  |  |
Expiration term |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |
Variable consideration included in transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  | 47,000,000.0 |  |  |  |  |
Collaboration revenue recognized from opening contract liability |  |  |  |  |  |  |  |  |  |  | 2,100,000 | 1,600,000 |  | 3,600,000 | 3,300,000 |  |  |  |
Recorded deferred revenue |  |  |  |  |  |  |  |  |  |  | 200,000 |  |  | 200,000 |  | 200,000 | 3,800,000 |  |
Gilead Agreement | License revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | $ 20,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Gilead Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of drug candidates | candidate |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |
Additional payments |  |  |  |  |  |  |  |  |  |  | 1,800,000,000 |  |  | 1,800,000,000 |  | 1,800,000,000 |  |  |
Sanofi Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Drug targets | target |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  | 3
Term extension |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  |  | 2,000,000.0 | 3,400,000 |  | 2,000,000.0 | 16,100,000 |  |  |  |
Upfront payment |  |  |  |  |  |  |  | $ 55,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Expiration term |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |
Variable consideration included in transaction price |  |  |  |  |  |  |  | $ 20,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Recorded deferred revenue |  |  |  |  |  |  |  |  |  |  | 0 |  |  | $ 0 |  | 0 | 0 |  |
Additional payment received to exercise option to expand number of targets |  |  |  |  |  |  |  | $ 22,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Additional drug targets | target |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |
Number of performance obligations | performanceObligation |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |
Contractual initial research period |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 years 3 months |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  | 3,100,000 |  |  | 9,100,000 |  |  |  |
Performance obligation satisfied |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 6,400,000 |  |  |  |
Sanofi Agreement | Sanofi Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research milestones payments received |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 22,000,000.0 |  |  |  |  |
Research and development milestone payments |  |  |  |  |  |  |  |  |  |  | 187,000,000.0 |  |  | 187,000,000.0 |  | 187,000,000.0 |  |  |
Certain sales milestones payments |  |  |  |  |  |  |  |  |  |  | 500,000,000.0 |  |  | 500,000,000.0 |  | 500,000,000.0 |  |  |
Regulatory milestone payments |  |  |  |  |  |  |  |  |  |  | 250,000,000.0 |  |  | 250,000,000.0 |  | 250,000,000.0 |  |  |
Sanofi Agreement | License revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue | $ 15,000,000.0 | $ 15,000,000.0 |  |  |  |  |  |  |  |  |  |  |  | 30,000,000.0 |  |  |  |  |
Sanofi Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Extended research term |  |  |  |  |  |  | 5 years 3 months |  |  |  |  |  |  |  |  |  |  |  |
Sanofi Agreement | Maximum | Sanofi Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional payments |  |  |  |  |  |  |  |  |  |  | 937,000,000.0 |  |  | 937,000,000.0 |  | 937,000,000.0 |  |  |
Sanofi Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Extended research term |  |  |  |  |  |  | 1 year |  |  |  |  |  |  |  |  |  |  |  |
Pfizer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  |  | 5,000,000.0 | $ 4,000,000.0 |  | 9,700,000 | $ 8,000,000.0 |  |  |  |
Variable consideration included in transaction price |  |  |  |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Recorded deferred revenue |  |  |  |  |  |  |  |  |  |  | 19,100,000 |  |  | 19,100,000 |  | 19,100,000 | 23,800,000 |  |
Number of performance obligations | performanceObligation |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual initial research period |  |  |  |  | 4 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Products arising from collaboration | product |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, current |  |  |  |  |  |  |  |  |  |  | 13,100,000 |  |  | 13,100,000 |  | 13,100,000 | 13,800,000 |  |
Contract assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000.0 |  |
Pfizer | Pfizer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  | $ 60,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research milestones payments received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,000,000.0 |  |  |
Additional payments |  |  |  |  |  |  |  |  |  |  | 3,400,000,000 |  |  | 3,400,000,000 |  | 3,400,000,000 |  |  |
Research and development milestone payments |  |  |  |  |  |  |  |  |  |  | 621,000,000.0 |  |  | 621,000,000.0 |  | 621,000,000.0 |  |  |
Target licensing and reservation payments |  |  |  |  |  |  |  |  |  |  | 19,500,000 |  |  | 19,500,000 |  | 19,500,000 |  |  |
Certain sales milestones payments |  |  |  |  |  |  |  |  |  |  | 1,800,000,000 |  |  | 1,800,000,000 |  | 1,800,000,000 |  |  |
Regulatory milestone payments |  |  |  |  |  |  |  |  |  |  | $ 873,000,000.0 |  |  | $ 873,000,000.0 |  | $ 873,000,000.0 |  |  |
Pfizer | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual initial research period |  |  |  |  | 6 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pfizer | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual initial research period |  |  |  |  | 4 years |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Additional payment received to exercise option to expand number of targets. + References No definition available. + Details
Name: | nrix_AdditionalPaymentReceivedToExerciseOptionToExpandNumberOfTargets
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Additional Payments + References No definition available. + Details
Name: | nrix_AdditionalPayments
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration agreement contract term. + References No definition available. + Details
Name: | nrix_CollaborationAgreementContractTerm
Namespace Prefix: | nrix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement Contract Term, Extension + References No definition available. + Details
Name: | nrix_CollaborationAgreementContractTermExtension
Namespace Prefix: | nrix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement Expiration Term + References No definition available. + Details
Name: | nrix_CollaborationAgreementExpirationTerm
Namespace Prefix: | nrix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract With Customer Liability Revenue Recognized Excluding Opening Balance + References No definition available. + Details
Name: | nrix_ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contractual extended research period. + References No definition available. + Details
Name: | nrix_ContractualExtendedResearchPeriod
Namespace Prefix: | nrix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual initial research period. + References No definition available. + Details
Name: | nrix_ContractualInitialResearchPeriod
Namespace Prefix: | nrix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Additional Specified Drug Targets + References No definition available. + Details
Name: | nrix_NumberOfAdditionalSpecifiedDrugTargets
Namespace Prefix: | nrix_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Drug Candidates + References No definition available. + Details
Name: | nrix_NumberOfDrugCandidates
Namespace Prefix: | nrix_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Performance Obligations + References No definition available. + Details
Name: | nrix_NumberOfPerformanceObligations
Namespace Prefix: | nrix_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Products Arising From Collaboration + References No definition available. + Details
Name: | nrix_NumberOfProductsArisingFromCollaboration
Namespace Prefix: | nrix_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Specified Drug Targets + References No definition available. + Details
Name: | nrix_NumberOfSpecifiedDrugTargets
Namespace Prefix: | nrix_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Proceeds From Collaboration Agreement, Clinical Milestone Payment + References No definition available. + Details
Name: | nrix_ProceedsFromCollaborationAgreementClinicalMilestonePayment
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Proceeds From Collaboration Agreement, Extension Payment + References No definition available. + Details
Name: | nrix_ProceedsFromCollaborationAgreementExtensionPayment
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research milestones payments received. + References No definition available. + Details
Name: | nrix_ResearchMilestonesPaymentsReceived
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount, Certain Sales Milestones + References No definition available. + Details
Name: | nrix_RevenueRemainingPerformanceObligationVariableConsiderationAmountCertainSalesMilestones
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount, Regulatory Milestones + References No definition available. + Details
Name: | nrix_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount, Research And Development Milestones + References No definition available. + Details
Name: | nrix_RevenueRemainingPerformanceObligationVariableConsiderationAmountResearchAndDevelopmentMilestones
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount, Target Licensing And Reservation + References No definition available. + Details
Name: | nrix_RevenueRemainingPerformanceObligationVariableConsiderationAmountTargetLicensingAndReservation
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront payment. + References No definition available. + Details
Name: | nrix_UpfrontPayment
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment of additional fees. + References No definition available. + Details
Name: | nrix_UpfrontPaymentOfAdditionalFees
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Variable consideration included in transaction price. + References No definition available. + Details
Name: | nrix_VariableConsiderationIncludedInTransactionPrice
Namespace Prefix: | nrix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A + Details
Name: | us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=nrix_LicenseRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nrix_GileadAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nrix_SanofiAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nrix_SanofiAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nrix_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nrix_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |